Skip to main content
Premium Trial:

Request an Annual Quote

Sticking Up for Avastin

Premium

FDA has granted Roche a public hearing to defend the effectiveness of Avastin in breast cancer, reports the Associated Press. Several months ago, the regulatory agency said the drug was "ineffective" in breast cancer — it's currently approved to treat colon, lung, kidney, and brain cancer — and in December, FDA began the process to revoke the drug's approval, AP adds. Roche's hearing is scheduled for June 28. The company's decision to challenge the ruling is "rare," AP says, and the meeting in June will be "the first of its kind."

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.